File: '\\swfile\EmailIn\20261009 123035 Attachment ASEP-L~1.DOC'

Asep Medical Holdings Inc.

1

FOR IMMEDIATE RELEASE

Asep Medical Announces LIFE FINANCING

VANCOUVER, BC, October 9, 2026 - Asep Medical Holdings Inc. ("Asep" or the "Company") (CSE: ASEP) (OTCQB:SEPSF) (FSE: JJ8) is pleased to announce that it intends to complete a non-brokered private placement financing under the Listed Issuer Financing Exemption (the "LIFE Offering") for maximum gross proceeds of $900,000.

The LIFE Offering will consist of a maximum of 9,000,000 units of the Company (each, a "Unit") at a price of $0.10 per Unit. Each Unit will consist of one common share in the capital of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one additional Common Share at an exercise price of $0.12 per Common Share, for a period of 24 months following closing

The Company intends to use the available funds from the LIFE Offering, together with its existing additional sources of funding, primarily for the identification and evaluation of companies and technologies for potential acquisition and integration into the Company's business, repayment of existing debts, and general working capital purposes.

The LIFE Offering is expected to close on or about October 30, 2026, or such other date or dates as the Company may determine, and may close in one or more tranches. The LIFE Offering is subject to the approval of the Canadian Securities Exchange. The Company has not engaged any dealers or finders in connection with the LIFE Offering, and no commissions, finder's fees or finder's warrants will be paid or issued in connection with the LIFE Offering.

The LIFE Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as modified by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, and is being made to purchasers resident in all provinces of Canada, other than Quebec. The securities issued pursuant to the LIFE Offering are expected to be immediately freely tradeable under applicable Canadian securities legislation.

There is an offering document related to the LIFE Offering that can be accessed under the Company's profile at SEDAR+ and on the Company's website. Prospective investors should read this offering document before making an investment decision.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any available exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is an investment issuer focused on investing into biotechnology research and development assets and is based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists. Asep holds a significant interest in two private companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin, Marketing Director ASEP Medical Holdings Inc.

E. chris@asepmedical.com

T. +1 (604) 362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include, but are not limited to, the completion and timing of the LIFE Offering, the issuance of the Units, Common Shares and Warrants, the intended use of available funds, and the receipt of approval of the Canadian Securities Exchange, the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.